Ampio enrolling patients for inhalable COVID-19 Phase I trial January 14, 2021 Auto Bot News 0 The immunotherapy-focused firm reports enromment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment.